Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing
(1d)
China’s Henlius carves out $440M T-cell engager deal with Amberstone
(1d)
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
(1d)
Merck sees pivotal victory for $3B eye disease prospect
(1d)
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
(1d)
Adagio Medical kicks off strategic review, trims more than half its staff
(1d)
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with InnoCare
(1d)
Grail survives adcomm vote as it awaits FDA decision for cancer blood test
(1d)
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
(2d)
Trump's Department of War bets $47M on Flagship biotechs to develop countermeasures
(2d)
Enveda reaps $311M series E to feed ambition to become a ‘household name’
(2d)
Immunovant ends cutaneous lupus program after phase 2 flop
(2d)
Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease
(2d)
Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
(2d)
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
(3d)
Novartis secures new radioligand in $900M deal as competition strengthens
(3d)
Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
(3d)
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
(3d)
Vertex’s midstage data amplify kidney disease market opportunity
(3d)
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
(3d)
BioPharma Dive
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
(7h)
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
(10h)
RNAi drug specialist ADARx raises $446M IPO
(23h)
Grail multicancer detection test wins FDA advisers’ backing
(1d)
FDA nominee Overton parries vaccine questions at Senate hearing
(1d)
Merck reveals study success, and possible safety worries, for eye drug hopeful
(1d)
Lilly’s latest China drug deal; Immunovant’s setback in lupus
(1d)
Enveda, an AI drugmaker, banks $311M in venture funding
(2d)
Roche, Ionis RNA drug scores in kidney disease study
(2d)
9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe
(2d)
Amgen reports a Phase 3 win with Sjögren’s drug candidate
(3d)
Viking shares surge on updated obesity drug data
(3d)
Celldex sinks as safety concerns cloud immune drug results
(3d)
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
(3d)
A hidden tradeoff in Trump’s drug pricing deals
(3d)
Beacon eye gene therapy hits mark in late-stage study
(4d)
Novo talks up drug launches in effort to win back investors
(4d)
Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
(4d)
How J&J paved the way for Compass’ coming psychedelic drug launch
(4d)
Are healthcare systems really ready for GLP-1s?
(4d)
Endpoints News
FDA approves Mirum’s drug for ultra-rare soft tissue disease
(4h)
Jury awards Nektar $90M in suit against Lilly
(6h)
Pharma industry asks FDA for more details on when one trial is enough
(7h)
To get drugmakers into ultra-rare disease, the answer isn’t rare disease at all
(8h)
Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split
(9h)
Endpoints 11 2026 winner Kali looked at China for pipeline drugs, then turned in-house
(9h)
Endpoints 11 2026 winner Azalea melds gene editing and CAR-T
(9h)
Endpoints 11 2026 winner NewLimit searches for a new class of anti-aging drugs
(9h)
Endpoints 11 2026 winner Anew Labs offers a China-based rival to AI labs
(9h)
Endpoints 11 2026 winner Stipple Bio is taking precision to the next level
(9h)
Endpoints 11 2026 winner Medra wants to create self-driving labs
(9h)
Endpoints 11 2026 winner SonoThera has a new approach to non-viral gene therapy
(9h)
Endpoints 11 2026 winner Medici believes the future of cancer therapy is personalized
(9h)
Endpoints 11 2026 winner Corsera is the latest big bet by Maraganore and Meanwell
(9h)
Biotech's best startups of 2026: Meet this year's Endpoints 11
(9h)
Endpoints 11 2026 winner K2 Therapeutics looks to marry China’s speed with global expertise
(9h)
Endpoints 11 2026 winner Vivodyne’s human tissue factory could change drug testing
(9h)
Merck expands Welireg's use to broader set of kidney cancer patients
(11h)
Alnylam alumni-led RNAi biotech City Therapeutics files for IPO
(12h)
Travere CEO Eric Dube on deciding to leave; Roche tees up a board seat for ex-Takeda chief
(12h)
BioSpace
After COVID, biomanufacturing tackles preparedness and commercialization challenges
(9h)
Nektar prevails in legal battle with Lilly over broken rezpeg partnership
(9h)
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
(10h)
J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma
(10h)
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
(11h)
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
(1d)
US senators grill FDA nominee Overton on ability to ‘stand up’ to Trump
(1d)
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
(1d)
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
(1d)
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
(1d)
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
(1d)
Backed by NVIDIA and Anthropic, Basecamp bags $140M to advance AI-designed drugs
(1d)
Backed by NVIDIA, Basecamp bags $140M to advance AI-designed drugs
(1d)
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
(1d)
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
(1d)
How radioligand therapy is rewriting cancer care
(1d)
The human cost of AI interviews
(1d)
Growth mode: 3 biotechs that are staffing up after series B raises
(1d)
Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss
(2d)
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
(2d)
STAT News
Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
(6h)
Lilly wins approval for once-weekly insulin shot
(8h)
FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
(9h)
Up and down the ladder: The latest comings and goings
(10h)
We’re reading about a reticent FDA commish nominee, a Novo deal, and more
(10h)
Federal judge rolls back landmark disability protections
(10h)
How Big Tobacco flooded the FDA with public comments to kill a menthol cigarette ban
(15h)
At least five candidates vie to become the next WHO leader, as questions over U.S. role loom
(15h)
The head of Kennedy’s new autism project served in Iraq War, worked with Sesame Street
(15h)
RFK Jr.’s use of the National Center for Health Statistics will add confusion to measles deaths count
(15h)
The ‘died with’ vs. ‘died of’ measles discussion misses something very important
(15h)
FDA commissioner nominee Heidi Overton keeps opinions to herself in Senate hearing
(1d)
The FDA’s Overton era, and dispatches from Shanghai
(1d)
Senate Finance committee backs Chris Klomp, advancing him to full Senate vote
(1d)
Indonesian ruling against ‘patent evergreening’ by pharma industry sends critical message, patient advocates say
(1d)
Kyverna’s cell therapy shows lasting autoimmune benefit
(1d)
We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and more
(1d)
The rise of the AI-native radiology practice
(1d)
One of the most contagious diseases on the planet is having its worst U.S. outbreak since 1991
(1d)
Why Gilead can’t stop talking about its ambitions in immunology
(1d)
BioPharma Trend
AI Drug Discovery Startups Raise $526 Million in Two Days
(1d)
Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?
(4d)
Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?
(5d)
Is “Rescuing Failed Drugs with AI” a Category Now?
(5d)
Is the Future of AI Drug Discovery Hybrid?
(5d)
The Bigger Point Beyond Insilico's Aging Research Milestone
(2w)
The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?
(2w)
What the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences
(3w)
Into the Dark: Finding Novel Drug Targets Within the Depths of Our Proteome
(4w)
Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms
(1mo)
Seven HealthTech Trends In Europe To Watch
(3mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(3mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(4mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(4mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(5mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(5mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(5mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(5mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(5mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(5mo)
Drug Channels
Why GoodRx Is Built for the AI-Driven Patient Journey
(13h)
The Spinoff: How Biosimilars Are Becoming Wholesalers' Next Hit Show
(3d)
Keep Your Patient Program at the Forefront of Innovation at Patient Pathways: The Copay and Patient Services Congress
(4d)
Fixing the Front Door Isn’t the Same as Fixing Time to Therapy
(1w)
Preorder DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
(1w)
Informa Connect’s Pharma/Biotech GTN Summit
(2w)
Drug Channels Leadership Forum 2027: Antonio Ciaccia to Serve as Moderator
(2w)
BlinkRx Insights: Beyond the Hub - Rethinking the Prescription Journey
(3w)
The Private Label Biosimilar Paradox in Medicare Part D
(3w)
Medicare, Medicaid, and Reverification: What Patient Support Programs Need to Know Before January 2027
(4w)
Drug Channels News Roundup, August 2026: 340B Rebate Model v2, Patients Feeling Drug Costs, Specialty Drug Spending Drivers, Impact on Coverage from the IRA, and a Drug Price Adventure
(1mo)
Invisible Work of Rare Pharmacy Delivers Highly Visible Patient Outcomes
(1mo)
REMS Removed: Why CAR-T’s Expansion into Community Oncology Could Benefit the Big Three Wholesalers
(1mo)
Hub Transitions Need Proven Plans, Smart Scale-Up
(1mo)
The K-Shaped Pharmacy Shakeout: Consolidation in Cities, Lost Access in Rural America
(1mo)
Informa Connect’s Medicaid Drug Rebate Program Summit
(1mo)
A System of Record, or a System of Learning?
(1mo)
Who Will Pay for Prescription Drugs in 2034? Medicare's Surprising Rise in the Latest Government Forecasts
(1mo)
The Industry Doesn't Have an Access Collaboration Problem. It Has an Accountability Problem.
(1mo)
Drug Channels News Roundup, Mid-July 2026: Biosimilar Launch Strategy, Part D Spending Trends, Rural 340B Hospitals, What Employers Can Do About 340B, and Drug Channel Villains
(2mo)
European Biotechnology Magazine
Bavarian Nordic names new CEO; Abivax and ProQR add key leaders
(15h)
Roche signs two deals worth about $3.5B in one day
(16h)
Nine pharma companies urge Europe to invest more in medicines
(1d)
Kasvu raises €30M for depression drug targeting TrkB
(1d)
Boehringer pays up to $250M to expand Variant Bio’s pact into heart disease
(1d)
Basecamp Research raises $140M for AI-designed cell therapies
(2d)
ViferaXS secures up to €12M for leukemia trial
(2d)
Scarlet gets $14M for smart red blood cells
(2d)
Roche hits Phase 3 IgAN endpoint but holds back data
(2d)
Cell therapies: breaking barriers in solid tumours
(3d)
Boehringer backs Envisagenics in $1B RNA splicing deal
(3d)
Big Picture Bio launches with £2.2M to design cancer combinations
(3d)
Remynd receives €3.5M for Alzheimer’s trial
(3d)
Novartis licenses BoomRay radioligand asset for $900M
(3d)
Beacon’s XLRP gene therapy meets pivotal U.S. endpoint
(4d)
Telix to acquire ITM for $1.65B in radiopharma push
(4d)
Matisse raises €14M for Phase 2 sepsis trial
(1w)
Novartis drops TREM2 antibody in ALS after Phase 2 miss
(1w)
Novartis pays $125M for Sironax brain delivery platform
(1w)
Orbis lands $1.4B macrocycle partnership with Novo
(1w)
Drug Hunter
QTX3034
(9h)
DAC 44
(1d)
Can Antibody Conjugation Offer a Path Forward for Genentech’s SMARCA2 Degraders?
(1d)
INCB161734
(2d)
ritonavir
(3d)
selgantolimod
(4d)
JNJ-2175
(1w)
AZD3632
(1w)
enpatoran (M5049)
(1w)
pociredir
(1w)
How Pyridazinones Mimic Amides, Phenols, and Nicotinamides
(2w)
Lessons from Recently Approved Oral Small Molecules: Dose Regimens, PK, and Safety
(2w)
Next-Gen Utrophin Modulators for DMD: Learning from Clinical Setbacks
(2w)
MK-1088
(2w)
diranersen
(2w)
TNG456
(2w)
EFMC Medicinal Chemistry 2026 First Time Disclosures
(2w)
Covalent Warhead Reactivity Cheat Sheet
(3w)
iberdomide (CC-220)
(3w)
golidocitinib (AZD4205 / DZD4205)
(3w)
Labiotech.EU
Theialife’s race to bring a childhood myopia treatment to market
(15h)
“An open and collaborative culture”: what makes Sweden attractive for life sciences
(2d)
AstraZeneca’s pipeline strategy: building the next wave of growth
(3d)
How to navigate the IND process and shorten DNA-to-IND timelines to 6 months
(3d)
What can GLP-1s do beside treat diabetes and obesity?
(4d)
WCLC 2026: The lung cancer drug development readouts that caught our eye
(1w)
The best biotech conversations you missed this summer
(1w)
Oncology biotech news: key moves to watch in September 2026
(1w)
New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?
(1w)
BIOSPAIN 2026: Spain’s flagship biotech event is going annual
(1w)
Beyond Ozempic: the GLP-1 landscape in 2026
(2w)
NLS Days 2026: what’s dealmaking like in the Nordics?
(2w)
Rewriting the rules of genetic medicine with tRNA therapeutics
(2w)
Preclinical Pulse: The research catching our eye in September 2026
(2w)
Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next
(2w)
Streamlining stable cell line development from the start
(2w)
When every treatment counts: How clinical trials are changing the outlook for non-Hodgkin lymphoma patients
(3w)
Top biotech deals in August 2026
(3w)
How Evox Therapeutics is targeting CNS diseases with exosomes
(3w)
Bladder cancer treatment: where are we standing in 2026?
(3w)
Bio IT World
A Field in Transition: T Cell Engagers
(1d)
Elsevier, LG AI Research Integrate Chemistry-Specific AI Vision
(2d)
Apheris Announced the Results of their Federated Learning Co-Folding Initiative—Now Four Big Pharma Are Betting Bigger
(3d)
AI Can Help Find New Uses for Old Drugs; Advancing Them to Patients Is the Hard Part
(1w)
A 1970s Lipid-Lowering Compound May Offer a New Approach to Obesity
(1w)
Lehigh Team Uses Digital Twin of Gut-Brain Axis to Advance Neurostimulation Therapies
(1w)
What It Takes to Make Generative AI Fit for GMP
(2w)
Ultima, NVIDIA, Google Partner on Pangenome-Aware Whole Genome Sequencing
(2w)
Clearing the Bench-To-Bedside Hurdle: Why Translational Medicine Needs to Start Earlier
(3w)
NVIDIA Acquires Hugging Face for $12.93 Billion
(3w)
Deep-Learning Tool Uses Long-Read Sequencing to Detect Cancer Mutations
(3w)
Trends from the Trenches: Rethinking Computational Workflows for Modern Genomics
(3w)
What Scientists Actually Need From AI
(4w)
Follow the Money: Biological Foundation Models, Automated Bioanalysis, Predictive Cancer Care
(1mo)
New CRISPR Screening Service, Calla Lily Joins Wellcome Leap’s Program, Baylor College to Establish Xenoliver Transplant Center
(1mo)
Psychedelics Reveal Immune Signatures Linked to Rapid Depression Relief
(1mo)
Multiomics Study Connects Clinical Phenotypes to Molecular Signatures in Down Syndrome
(1mo)
Quality Leaders Warn Against Digitizing Broken Processes
(1mo)
The End of the ‘One-Size-Fits-All’ Parkinson’s Diagnosis: Why 2026 Is the Year Neurology Goes High-Resolution
(1mo)
Human Longevity Launches $600 Whole Genome
(1mo)
GEN News
Thar Process Partners with ExtrateX to Bring Prep to Process-Scale SFC to Europe
(5h)
How Bladder Cells Fight Hidden E. coli: New Insights Into Recurrent UTIs
(5h)
Stroke Remodels Tumor Microenvironment to Promote Glioma Growth
(7h)
New CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages
(14h)
APOE4 Linked to Potentially Reversible Mechanisms of Brain Blood Vessel Damage in Alzheimer’s
(1d)
Muscle Cell Calcium Channel Structure, Synchronicity Could Advance Muscle Disease Therapeutics
(1d)
JNC Targets Bigger Molecules with Cellufine
(1d)
Intense Media Pressure an Emerging Challenge in CHO Business
(1d)
Altruist Biologics’ Suzhou Site Receives EMA GMP Certification
(1d)
New Liposome Design Could Provide Effective Slow-Release Drug Delivery System
(2d)
Tautomer-Predictor AI Tool Identifies Stable Molecules for Drug Discovery
(2d)
Genialis and Inventia Life Science Collaborate to Link Patient Biology with 3D Pancreatic Cancer Models
(2d)
Digital Shadows to Aid Complexity in Handling Process Intensification
(2d)
Media Cleaning Could Help Biopharma Cut Costs and Fully Embrace Perfusion
(2d)
CGT Collaboration Moves from Aspirations to Infrastructure
(2d)
Multi-Controller System: Major Boost to Continuous CHO Perfusion
(2d)
Anthropic-, Nvidia-Backed Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs
(2d)
Biomimetic Nanoparticles Trigger Light Responses in Blind Mouse Retinas
(3d)
Cell Senescence ‘Barcodes’ Identified with Raman Microscopy and Gene Expression Data
(3d)
Syngene Expands Integrated Drug Development and Manufacturing Services with BMS
(3d)
Cure Today
How Paxalisib Is Being Studied in Treatment-Resistant Breast Cancer
(3h)
Three August Blood Cancer Approvals and What They Mean for Care
(4h)
Walking Linked to 26% Lower Odds of Severe Fatigue After Colorectal Cancer
(6h)
How to Preserve Your Own Hair During Cancer Treatment
(7h)
Could a Genomic Test Spare You Extra Years of Hormone Therapy?
(9h)
We Eat Bagels Before Cancer Treatment. Here’s Why.
(10h)
What to Do Before Your Chemo Infusion: A Checklist From People Who've Been There
(1d)
How CAR-T Cell Therapy Is Changing Treatment for Childhood Leukemia
(1d)
FDA Approves Welireg Plus Lenvima for Advanced Kidney Cancer After Immunotherapy
(1d)
7 Breast Cancer Clinical Trials Currently Enrolling in the US
(1d)
My Sister and I Share a BRCA2 Mutation. We Didn’t Make the Same Choices
(1d)
10 Things That Got Me Through Treatment feat. Sally Kalksma
(2d)
Text a Survivor: Brad Moore on Life During and After Rectal Cancer Treatment
(2d)
FDA Approves Lyrfigtu for Previously Treated FGFR2-Positive Cholangiocarcinoma
(2d)
CAR-T and Targeted Drugs May Help High-Risk Childhood Leukemia
(2d)
Mindfulness and Tai Chi Help Improve Fatigue and Pain After Cancer Treatment
(2d)
From Distress to Resilience: Supporting the Psychosocial Needs of Lung Cancer Patients and Families” at LiveLung Marietta Meeting
(2d)
Getting Ready to Swim in a Sea of Pink
(2d)
Paxalisib Trial Expands to HR-Positive, HER2-Negative Breast Cancer
(3d)
Finding the Words: How to Talk to Someone With Cancer
(3d)
Contract Pharma
Contract Pharma 2026 Conference Concludes with Risk Management Forum
(3h)
Reducing Product Loss in Sterile Manufacturing
(8h)
SK pharmteco Launches Catalyst Kit
(8h)
Recipharm, CanVirex Partner on Oncolytic Virus Manufacturing
(8h)
The Friday Brief for September 25, 2026: Live from Contract Pharma 2026
(9h)
Inside CPHI Milan’s New Sustainability Summit
(1d)
Cellares, SNUH Partner on Cell Therapy Manufacturing - contractpharma.com
(2d)
AustinPx KinetiSol Earns FDA AMT Designation - contractpharma.com
(2d)
Contract Pharma Announces New Bio Outsourcing Conference in Cambridge
(2d)
Astoriom Acquires Roylance Stability Storage and Roylance Scientific - contractpharma.com
(2d)
CDMOs’ new capacity skews stainless by liters, but single-use leads by system count - marketscale.com
(3d)
Longhorn Vaccines and Diagnostics Names Dr. Vijay Singh Chief Scientific Officer
(3d)
James Alexander Corporation Becomes 100% Employee-Owned
(3d)
ExploRNA, Łukasiewicz Research Network Partner on GMP Manufacturing of Next-Gen mRNA Cap Analogs
(3d)
Sanner Rebrands Gilero, Expands Chicago Facility
(3d)
Travere Therapeutics Names Bradley Campbell CEO
(3d)
Lilly Breaks Ground on $6.5B Houston Manufacturing Site
(3d)
FDA Approves IntraBio’s Aqneursa as First Treatment for Ataxia-Telangiectasia
(4d)
Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer
(4d)
Codis Promotes Steven Facer to Chief Commercial Officer
(4d)
Pharma Times
Japan approves prefilled syringe for GSK’s shingles vaccine
(1w)
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
(1w)
Zerion partner files first EU application for Dispersome‑enabled product
(1w)
Tozorakimab shows broad COPD benefit in new phase 3 data
(1w)
Study highlights advance in influenza protection for older adults
(1w)
NICE backs daratumumab quadruplet for transplant‑eligible myeloma
(1w)
Teitur reports positive early data for Parkinson’s peptide TT‑P34
(2w)
Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer
(2w)
NICE backs ibrutinib regimen for untreated mantle cell lymphoma
(2w)
Livdelzi accepted in Scotland for treatment of PBC
(2w)
Jemperli accepted for priority review by US FDA
(4w)
Carterra supports AI‑designed protein study with HT-SPR platforms
(4w)
Erasca secures FDA fast track for eras‑0015 in pancreatic cancer
(4w)
Avulux gains FDA authorisation for migraine light‑sensitivity lens
(4w)
Leqembi Iqlik launches in US for early Alzheimer’s
(1mo)
Lundbeck gains EU orphan status for anti‑ACTH antibody
(1mo)
AC Immune reports positive phase 1 data for ACI‑19764
(1mo)
VarmX begins global phase 3 trial of VMX C001
(1mo)
VarmX begins global phase 3 trial for VMX C001
(1mo)
FairJourney Bio unveils tumor‑conditional IL‑12 breakthrough
(1mo)
Medcity News
Report: High Drug Costs Are Creating Hidden Burden for Physicians
(1h)
Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut
(4h)
AI Goes All In To Support Nursing Teams: Ambient Charting is Just the Start
(9h)
UHC, Cigna and Centene Sign On to New National Shared Credentialing Program
(1d)
Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact
(1d)
From OpenNotes to “Doc Can I Record You?” Why Physicians Should Embrace Era of Accountability
(1d)
Modernizing Medicare Advantage for the Next Generation of Seniors
(1d)
Phase 3 Data Could Make Roche Drug a Contender to Treat Rare Kidney Disease`
(2d)
Teal Health Secures $22M for At-Home HPV Cervical Cancer Screening Device
(2d)
Who is Abridge’s CEO Shiv Rao? No, Really…
(2d)
Innovation in Oncology: The Synergy of New and Old Drugs
(2d)
Pelago Unveils New Behavioral Health Platform for Substance Use, Mental Health and Behavioral Addiction Care
(3d)
How is Oracle Health’s Nurse AI Agent Different?
(3d)
Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds
(3d)
AI Workers Need a Probation Period, Not Just a Pilot
(3d)
Radiopharmaceutical Dealmaking Continues With Telix’s $1.65B ITM Acquisition
(4d)
Array Behavioral Care Unveils New Triage Model
(4d)
How AI Is Transforming Clinical Documentation at Intermountain Health
(4d)
The Nurse Is Health Care’s Most Underpriced Founder
(4d)
Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugs
(5d)
Chemical & Engineering News
BASF is in talks to buy Evonik
(4h)
At Climate Week, technology is still a solution to climate change
(6h)
Policy Watch: HHS and EPA move to coordinate on glyphosate review
(8h)
How wildfire smoke put Bordeaux’s wine at risk
(9h)
C&EN weekly chemistry news quiz, Sept. 25
(9h)
Wilfred A. van der Donk wins 2026 A. I. Scott Medal
(10h)
This battery is ready to eat
(1d)
Phosphate steps into new role as autonomous molecular machine
(1d)
Reading 2000-year-old scrolls without unfurling them
(1d)
Skeletal-editing ‘dream’ realized
(1d)
Ineos to shutter UK acetyls plants
(1d)
Kasvu Therapeutics goes after a different neuroplasticity target to treat depression
(1d)
White House reportedly retreating from plan to control NIH grants
(2d)
Chemistry in Pictures: Fluorescent tube
(2d)
Ultrasensitive heat sensor tracks X-rays from nuclear materials
(2d)
What you need to know to register for ABCChem
(2d)
Chemical industry groups, GAO press DHS to resume terrorist-screening program
(3d)
Business Watch: Ineos opens Danish carbon storage site, and more
(3d)
This nanomaterial stimulates the body’s bone-growing process
(3d)
Living up to the legacy of a 135-year-old local section’s first authorized award
(4d)
The Pharma Letter
Zenbexus doubles MRD-negative complete response rate in pivotal myeloma trial
(8h)
Nanexa soars on Novo deal for injection technology
(8h)
China expands role in manufacturing new FDA-approved drugs - thepharmaletter.com
(9h)
Merck’s Ogsiveo greenlighted by NICE - thepharmaletter.com
(9h)
Carvykti delivers five-year treatment-free remission in half of early-line myeloma patients - thepharmaletter.com
(9h)
Addex rises as it regains GABAB portfolio from Indivior
(11h)
Kyverna's miv-cel shows durable one-year benefit in stiff person syndrome and myasthenia gravis
(11h)
European Commission approves Nezglyal for rare brain disease
(11h)
FDA commissioner pick pledges to follow statutory requirements in FDA hearing
(11h)
FDA approves Welireg and Lenvima combo for advanced kidney cancer
(11h)
AstraZeneca registers new hypertension drug in Russia
(13h)
FDA approves Lilly's once-weekly basal insulin Onswik for type 2 diabetes
(13h)
Russian SMA patients experiencing shortage of original drugs
(14h)
Health Canada approves Epkinly for follicular lymphoma
(14h)
Tortugas Neuroscience names Ramzi Benamar as CFO
(15h)
Confirmatory trials and the new realities of FDA expedited approval - thepharmaletter.com
(15h)
EIB backs VaxThera with 35 million euros to boost Latin American vaccine capacity
(1d)
EIB backs VaxThera with 35 million euros to boost Latin American vaccine capacity
(1d)
MHRA approves Roche's Gazyvaro for systemic lupus erythematosus
(1d)
FDA approval for Lantheus’ Bravnetsa
(1d)
Targeted Oncology
Durvalumab-EV Perioperative Regimen Receives FDA Priority Review in MIBC
(3h)
Rethinking Transplant Eligibility in Multiple Myeloma in the MRD Era
(5h)
IMS 2026 Day 3 Recap: Etentamig Outperforms Standard Therapy in RRMM Trial
(6h)
Etentamig Shows Success With Focus on Tolerability, Administration in Relapsed Myeloma
(7h)
Etentamig Improves Response, PFS in Triple-Class Exposed Myeloma
(8h)
Biomarker Testing and Unmet Needs in Gastric/GEJ Cancers
(10h)
Annual Report Shows Continued Progress in US Cancer Outcomes
(10h)
Dr Hans Lee on New IMS/IMWG Criteria for Defining Cure in Myeloma
(1d)
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
(1d)
FDA Panel Votes in Favor of Galleri Multi-Cancer Early Detection Test
(1d)
IMS Day 2 Recap: MRD-Guided Maintenance, Novel Bispecific Data in Myeloma
(1d)
SOT106 Receives New FDA FTD and ODD in Sarcoma
(1d)
Kaur Discusses the Declining Role of Autologous Transplant in Myeloma
(1d)
FDA Approves Lirafugratinib for FGFR2-Altered Cholangiocarcinoma
(1d)
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
(1d)
ASTRO 2026 Preview: Dr Raj Singh on De-Escalation, Brain Metastases, and What's Next in Radiation Oncology
(1d)
Life-Years Saved Captures Gains—and Gaps—in Blood Cancer Treatment
(2d)
The Expanding RAS-Directed Pipeline in Pancreatic Cancer
(2d)
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
(2d)
177Lu-Dotatate Radioequivalent Earns Final FDA Approval in GEP-NETs
(2d)
MedWatch
GSK reprimanded for lack of transparency in vaccine campaign case
(14h)
Low expectations could turn into an advantage for Novo in 2027, says Saxo strategist
(14h)
Nanexa deal shows Novo's appetite for new growth avenues, analyst says
(14h)
Hemab Therapeutics reshuffles board
(15h)
MSD’s eye drug meets primary endpoint in trial
(15h)
Roche pays Atavistik Bio USD 70m upfront in research partnership
(16h)
Lundbeck moves US headquarters to Boston and opens innovation hub
(16h)
Novo signs deal worth up to EUR 1.165bn with Sweden's Nanexa
(16h)
Scantox CFO steps down after acquisition spree, successor hired from outside
(1d)
Xellia returns to profit after years of heavy losses and strategic shift
(1d)
Eli Lilly signs deal worth up to USD 3.35bn with China's InnoCare
(1d)
EU approves AstraZeneca's Trixeo for asthma maintenance treatment
(1d)
Bristol Myers Squibb announces 265 additional job cuts
(1d)
Potential US listing could bring Novo Nordisk closer to S&P 500
(1d)
ALK must wait on subsidy ruling for grass allergy drug
(1d)
Linak targets DKK 5bn in revenue under new CEO
(1d)
Novo shares post worst capital markets day reaction in a decade
(2d)
Novo can reach tenfold production target despite market uncertainty, investors say
(2d)
Roche proposes former Takeda CEO Christoph Weber for board seat
(2d)
GN shares rise as major bank sees potential for significant revaluation
(2d)
In The Pipeline
AI Help for Biological or Chemical Weapons
(1d)
As Close to Carbyne As We're Probably Going to Get
(2d)
tRNA Therapy
(3d)
Yet Another Attempt to Strangle Scientific Funding
(4d)
Safety Warning: Carborane Mixtures
(1w)
The Latest On CAR-T: Good and Bad
(1w)
The ACS Redesign
(1w)
Not The Glue They Thought It Was
(2w)
The State of AI Antibody Design
(2w)
Phosphorylate and Spare Not
(2w)
More Impossible-to-Ignore Vaccine Effects
(2w)
GLP-1 Drugs for Aging?
(3w)
Mutate 'Em All and See If You Can Sort 'Em Out
(3w)
Crappy Antibodies, Made Superficially More Appealing
(3w)
The Alleged Dimethylmercury Incident
(4w)
On vacation until August 31
(1mo)
The Fault Is Not In Our Trees, But In Ourselves
(1mo)
Merck and Moderna's Melanoma Results
(1mo)
More Alzheimer's Research Trouble
(1mo)
A New Alzheimer's Therapy - Or Is It?
(1mo)
Pharmaphorum
EU clears first drug therapy for rare disease cALD
(11h)
FDA starts speedy review of Imfinzi in bladder cancer
(12h)
FDA nominee Overton dodges questions on Trump influence
(13h)
Wnt drug gives MSD first eye disease win after EyeBio deal
(15h)
Australia starts probe into AI infiltration of Medicare
(1d)
Lilly's rival to Novo's new Awiqli insulin gets FDA approval
(1d)
Kyverna builds case for CAR-T in stiff person syndrome
(1d)
Lilly forges $3.35bn alliance with China's InnoCare
(1d)
Grail cancer test gets lukewarm backing from FDA adcomm
(1d)
AI specialists Enveda and Basecamp rake in the cash
(2d)
Roche, Viking, and Syntis showcase obesity drug candidates
(2d)
Roche's IgAN hopeful sefaxersen passes phase 3 test
(2d)
Amgen's Horizon buyout delivers Sjögren's disease win
(2d)
Pharma leaders urge Europe to halt 'slow agony' of decline
(2d)
UK issues £45m funding call for research partnerships
(2d)
UK needs 'clearer path for dementia diagnosis and treatment'
(3d)
Iambic files IPO after signing up AbbVie as new partner
(3d)
UK first country to launch CSL's trivalent flu shot Aujemflu
(3d)
Advocacy group pokes holes in Trump's MFN pricing claims
(3d)
ADARx, Trex, and Retension take aim at IPOs
(4d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(3mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(3mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(3mo)
Therapy enables 89% survival rate in myeloma patients
(3mo)
Ulcerative colitis treatment shows best-in-class potential
(3mo)
UK patients to benefit from approval of weight loss tablet
(3mo)
Vertex presents new data on Casgevy in children
(3mo)
DDW Highlights: 16 June 2026
(3mo)
LXR inverse agonist shows promise in liver disease
(3mo)
Guide: One solution – from R&D, to QC
(3mo)
A potentially practice-changing advance in bile duct cancer
(3mo)
Webinar: Consolidate multiple assays into a single, comprehensive AVA test
(3mo)
JAK inhibitor for VEXAS syndrome gets orphan drug designations
(3mo)
Whitepaper: How workflow scheduling software can answer the demands of automated labs
(3mo)
PhoreMost advances brain cancer programme to trial
(3mo)
Oriva appoints Arbat as CEO, advances endometriosis asset
(3mo)
Decoding Pan-RAS(ON) inhibitor activity across KRAS models: Webinar
(3mo)
This week in Drug Discovery (8 June – 12 June)
(3mo)
Laverock reports positive data from oncology programmes
(3mo)
GSK acquires Nuvalent and cancer therapy pipeline
(3mo)
HIT Consultant
Basalt Health Raises $20M to Scale Post-Acute AI Transition Platform Across 111 Markets
(1d)
CancerIQ Expands Native Epic Integrations to Automate Cancer Screening and Survivorship Across 275 Clinics
(1d)
Everlywell Appoints Chief Commercial and Product Officers to Expand Payer Diagnostic Care Platforms
(1d)
Hims Launches AI-Native Weight Loss Care Platform Featuring Closed-Loop Action Engine and Clinical Escalation
(1d)
Oracle Health Partners with ID.me to Embed Reusable Digital Identity Across Patient Portals and EPCS
(1d)
Trilliant Health Launches Oria AI Strategist to Replace Manual Healthcare Advisory
(1d)
Ensemble Health Partners with Penelope to Shift Real-Time Policy Intelligence Upstream
(1d)
America’s Elder-Care Crisis Has Arrived. We’re Not Ready.
(1d)
UltraSight Secures $24M to Scale Point-of-Care Cardiac Ultrasound Across Health Systems
(2d)
Vonage Brings Branded Calling to Epic Hello World to Drive 45% Patient Answer Rates
(2d)
Theranica’s 53,000-Patient Study Proves 30-Day Longitudinal Patterns Predict Migraines with 91% Precision
(2d)
CertifyOS Launches National Shared Credentialing with UnitedHealthcare, Cigna, and Centene
(2d)
Oracle Health Unveils Upstream AI Revenue Cycle Portfolio at Health and Life Sciences Summit
(2d)
Healthcare AI Governance: Moving from Data-Sensitivity Tiers to Reversibility Controls in Agentic Systems
(2d)
Heidi Secures $340M to Transition from Clinical Documentation to Supervised Agentic Execution
(3d)
Beyond Hospital Pre-Merger Notice: PESP Report Reveals States Are Targeting Private Equity Control via MSOs, Debt, and Sale-Leasebacks
(3d)
Healthcare Doesn’t Need Forward Deployed Engineers. It Needs Forward Deployed Operators.
(3d)
Abridge Wins Seat on $775.7M VA Enterprise Contract to Power Ambient Clinical AI
(3d)
Zocdoc Launches Care Access Network to Make Providers Bookable Across Gemini, Amazon Health AI, and Search Engines
(3d)
DexCare Acquires AI Care Coordination Platform Mila Health to Unify Patient Access and Conversational Scheduling
(4d)
Insights: Pink Sheet
Three Topics Dominated US FDA Commissioner Nominee Overton’s Senate Hearing
(1h)
Industry Pushes US FDA To Define ‘Highly Persuasive’ Single-Trial Bar
(2h)
Rosa Sherafat Takes Over US FDA Gene Therapy Clinical Review Office
(2h)
Another China Biotech Warning: Analysis Shows China Passes US In Oncology Approvals
(6h)
Pink Sheet Podcast: Lessons From US FDA Commissioner Nominee Heidi Overton’s Confirmation Hearing
(7h)
Recent And Upcoming US FDA Advisory Committee Meetings
(7h)
In Case You Missed It: GDUFA IV Deal Gives CMOs More Say, Defuses ‘Potential OAI’ Pain Point
(8h)
New EU Filings
(9h)
Will EU Pharma Reform Package Limit Appeal Of Smaller Markets In US MFN Era?
(9h)
UK To Close Regulatory Gaps With £20m Research Push
(10h)
Overton Calls MMR Vaccine ‘Not Lethal,’ Defends Trump’s Claim As Outreach To Vaccine Skeptics
(1d)
Medicare Negotiation Selection Process Needs Sharper Focus On Patent Expirations
(1d)
US FDA Commissioner Nominee Overton Says Panels Are ‘Critical,’ Hedges On Mifepristone Safety
(1d)
BsUFA IV Agreement Includes Push To Reduce Revenue, Cuts Product Development Fees
(1d)
Endpoints, Study Duration: EMA Sets Out Evidence Bar For Sickle Cell, Thalassemia Drug Approvals
(1d)
Is USTR German Pricing Probe Turning Reimbursement Policy Into A Trade Issue?
(1d)
‘Not A Numbers Game’: EMA Pushes Back On US FDA’s Single Pivotal Trial Default Standard
(1d)
Tariffs Round Two: The Sept. 29 Reckoning For API Makers Without A Deal
(1d)
China Eyes Central Role On Global Biopharma Stage
(1d)
Former FDA Commissioners’ Backing May Help Overton Amid Stakeholder Opposition
(2d)
BioXconomy
Sanofi’s regulatory leader breaks down ICH’s regulatory submission overhaul
(5h)
Avoiding the foul ball: Manufacturing siRNAs to improve patient adherence
(7h)
China's InnoCare lands up to $3.35bn Lilly deal
(8h)
How AI is streamlining patient support behind the scenes
(10h)
How AI is streamlining patient support behind the scenes
(10h)
Dispatches from CGT International: Big pharma M&A is the new biotech IPO
(14h)
The M&A paradox: Why signing the deal is just the beginning
(1d)
AI drug hunter Iambic files for Nasdaq IPO
(1d)
Kasvu raises $34m to develop alternative treatment for depression
(1d)
Trial management strategy outweighs service model in predicting study success
(2d)
Enveda’s $311m Series E to fund AI-driven drug discovery
(2d)
HighLife banks over $90m to launch US study and advance European commercial growth
(2d)
Dose of Discovery: Katalin Karikó on the mRNA breakthrough that changed medicine
(2d)
Physicians say 96% of patients quit meds due to cost without telling them, survey finds
(3d)
MHRA warns inadequate eHR systems are costing UK hospitals clinical trials
(3d)
Telix to buy ITM for $1.65bn upfront in radiopharmaceutical consolidation play
(3d)
Envisagenics' AI platform attracts $1bn+ pact with Boehringer
(3d)
FDA pilot program pairs sponsors with research sites to expedite Phase I trials
(4d)
Ten biopharma companies name new finance chiefs
(4d)
AI’s dual reality in finance and accounting—Navigating value, talent, and strategy
(4d)
BioCentury
Network Bio: Building disease-specific AI models with biobank data
(23h)
Enveda’s latest megaround puts $311M behind AI push: Venture Report
(23h)
Overton vows speed, deference to staff reviews, if confirmed to lead FDA
(1d)
How Europe’s VCs are chasing NewCo deals in China
(2d)
Amicus vet Campbell to succeed Dube as Travere CEO
(2d)
Science Spotlight: Degrading proteins without ubiquitin
(2d)
Led by the U.S. and China, radiopharma financing reaches new heights
(3d)
Tariff guidance leaves companies in the dark
(3d)
ShennonBio: Mining rare T cells for solid tumor therapies
(3d)
Beacon edges ahead in XLRP gene therapy race with Phase III hit
(4d)
Telix-ITM merger aims to create radiopharma juggernaut: Deals Report
(4d)
Biotech IPOs, CAR T safety, and pharma tariffs — a BioCentury podcast
(4d)
Chugai’s Lasker winners aim to beat their own blockbuster
(4d)
PDUFA VIII aims to remove CMC bottlenecks, shore up FDA staffing
(4d)
Fatal toxicities test autoimmune CAR T’s safety thesis
(7d)
Ultragenyx wins first approval for MPS IIIA, closing a bumpy four-year path
(7d)
EMA’s CHMP backs eight new medicines in September
(7d)
Sanofi vet Tarja Stenvall to lead Bavarian Nordic
(7d)
Electra dips after pricing upsized IPO, bucking trend: Public Equity Report
(1w)
Twelve days to go and pharma tariff rules are a total mystery
(1w)
SCRIP
Mirum’s Atebrioz, First Oral Approved For FOP, To Face Regeneron’s Pasatru
(1h)
Merck’s Withdrawal Of Recarbrio Takes It Off The Antibiotic Board
(2h)
Finance Watch: Big Money Keeps Flowing To AI-Enabled Drug Discovery And Development
(6h)
Mid-Sized Pharma And Lilly Setting M&A Pace In 2026
(7h)
The Eight Potential Immunological Blockbusters Coming To Market In 2027
(10h)
Executives On The Move: Jasper Therapeutics Bolsters Leadership After Kira Merger
(10h)
‘SNAC’ Bar: Novo Turns Up Heat In India Oral Semaglutide Patent Battle
(10h)
FDA Nod For Welireg-Lenvima Extends Merck’s Push Across The RCC Pathway
(10h)
Should Pharma Use Its PR Clout Against Climate Damage?
(13h)
Do API Exporters Really Need To Brace For The Sept. 29 Deadline Of US Tariffs?
(14h)
Norstella Launches Capsul, A Daily Intelligence Brief For Pharma and Biotech
(17h)
Acadia Alters Phase III Trials To Help Remlifanserin Succeed In Alzheimer’s Psychosis
(1d)
Lilly Joins Novo On Weekly Basal Insulin Market With FDA Nod
(1d)
The Race To The First Psychedelic Drug Approval Is On
(1d)
Due Diligence: Is Big Pharma Interest In Psychedelic Medicine Blooming?
(1d)
Alexion Aims To Enter Crowded gMG Space With Convenience Advantage For Gefurulimab
(1d)
Merck’s Wnt Agonist Is Efficacious As New Mechanism For Eye Disease
(1d)
Publisher’s Spotlight: Scrip Awards Announces 2026 Finalists
(1d)
Lilly Adds Another China Partner With InnoCare $100m Upfront Deal
(1d)
Kasvu All Set To Advance New Class In Depression
(1d)